Introduction
Breast cancer is the most frequent type of malignancy and the leading cause of cancer deaths of women in both developed and developing countries [1] . The majority of patient deaths are due to the growth of disseminated tumor cells in distant organs, i.e., metastasis. Among all the human organs, bone is the most favorite target of metastatic breast cancer cells [2] . Bone metastasis affects over 70% of the patients with advanced diseases, leading to intractable pain, bone fragility, nerve compression, hypercalcaemia, leukoerythroblastic anaemia and eventually patient demise [3] . Therefore, it is a pressing need to uncover the molecular underpinning of bone metastasis in order to develop effective therapies for breast cancer.
The development of tumor metastasis tumors depends on the mutual communication between cancer cells and their stromal milieu. The molecular interactions of metastasizing tumor cells with host cells and extracellular matrix (ECM) enable the tumor cells to modify the stromal components and turn them into accomplices for ECM remodeling, immune suppression, host tissue destruction and angiogenesis, all of which are essential for metastasis [4] . It is generally conceived that tumorderived secreted factors play critical roles in this abetting process [5, 6] . A plethora of secreted proteins have been shown to direct the cell-cell and cell-microenvironment interactions that drive cancer spreading. For example, cytokines are often found to mediate the directed migration of cancer cells during metastasis [7] , and induce the infiltration of inflammatory cells with pro-tumor characteristics in advanced-stage carcinoma [8] . Proteinases represent another important class of environmental molecules that regulate ECM remodeling, cancer cell invasion and cytokine mobilization [9, 10] . Some metalloproteinases, such as MMP1 and MMP2, are well known for their roles of enhancing distant metastasis through their proteolytic activities [9] . In addition, growth factors are widely reported to function in various metastasis-associated processes including cancer cell epithelial-mesenchymal transition, migration, invasion, survival and angiogenesis [11] . Tumor-secreted proteins cannot only remodel the local microenvironment for tumor spreading, but also manipulate distant tissues to facilitate future metastasis. They reach target organs ahead of metastasis cancer cells and adapt the foreign tissues into a tumor-friendly environment that is called "metastasis niche" [12] . Overall, cancer cell secretome is a rich reservoir of biomarkers of cancer progression and molecular targets of cancer therapeutics, and thus is a topic of great interest for cancer research [5, 13] .
Proteomics provides a powerful way to identify and compare secreted proteins in different cell lines or tissues. With recent advance of proteomic techniques, an increasing number of studies have characterized the cancer cell secretomes associated with cancer initiation, progression and chemoresistance [14] [15] [16] [17] [18] [19] [20] , which have greatly enriched our understanding of the roles of secreted proteins in cancer, and provided a good resource of cancer-specific biomarkers with potentials of therapeutic application. However, fewer studies have been focused on proteomic analyses of cancer secretomes related to metastasis. Among the pioneering work of metastasis secretome analyses, Kreunin et al. [21] profiled the proteins in the conditional medium (CM) of a pair of M DA-MB-435 derivative cell lines with different metastatic phenotypes. Several proteins such as OPN and ECM1 were found to be enriched in the medium of metastatic cells. Rocco et al. [22] performed secretome profiling of several cancer cell lines from different metastases of a melanoma patient and found that a list of matricellular proteins including SPARC, OPN and ECM1 were associated with melanoma metastasis. Mbeunkui et al. [23] analyzed the secretomes of the MCF10 cell line series, a model of breast cancer progression, and identified five proteins highly secreted by the more aggressive cells. Similarly, Xue et al. [24] studied the secreted proteins of the colorectal cancer cell line SW480 and its metastatic subline SW620. Among the differentially expressed proteins, TFF3 and GDF15 were further shown to be correlated with lymph node metastasis of clinical samples. Several more studies reported differentially secreted proteins associated with metastasis of melanoma, lung cancer and ovarian cancer [25] [26] [27] [28] . However, so far systemic analyses of tumor-derived soluble proteins correlated with bone metastasis have been lacking, and thus the nature of changes in protein secretion leading to this frequent complication of cancer remains elusive.
In the present work, we performed liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based secretome profiling for four derivative lines of MD231 with varied tendencies of bone metastasis. A total of 2 069 proteins were identified in the CM of cancer cells, among which 128 species displayed differential secretion levels in these cell lines. Notably, proteinase inhibitors were significantly enriched in the regulated proteins, indicating a critical role of proteinase activities in the tumor environment during breast cancer bone metastasis. In the functional validation, we showed that one of the proteinase inhibitors, CST6, suppressed the migration, invasion and in vivo bone metastasis of breast cancer cells. Furthermore, CST6 played the metastasisinhibiting role in its soluble form, supporting that it is a secreted suppressor of metastasis.
Results

Secretome analysis of breast cancer bone metastasis
In order to characterize the secreted proteins associated with breast cancer bone metastasis, we took advantage of the MDA231 derivative cell line model. By single cell progeny (SCP) cloning, Kang et al. [29] established a series of sublines from MDA231, a cell line obtained from the pleural fluid of a patient with metastatic breast cancer. Among the MDA231 derivatives, SCP2 and SCP46 developed osteolytic bone metastasis rapidly when injected intracardiacally into immunodeficient mice, while SCP4 and SCP6 displayed much weaker metastasis capabilities. Since then this cell line model has been widely used to study the molecular and stromal mechanisms of breast cancer bone metastasis [30] [31] [32] [33] [34] . We performed secretome profiling of SCP4, SCP6, SCP2 and SCP46 cells with LC-MS/MS following one-dimensional gel electrophoresis and in-gel digestion (1D GeLC-MS/MS). In the workflow elaborated in Figure 1 , serum-free CM of the four cell lines were collected individually, and three independent technical replicates of each line were ana- 998 proteins were detected in all the three replicates of each cell line, accounting for 71.2%, 67.8%, 66.0% and 70.1% of the identified proteins ( Figure 2A ). In general, we achieved a technical reproducibility of 80.0% ± 3.1% for any two replicates and 68.8% ± 2.3% for three replicates.
We further analyzed the subcellular localization of the identified proteins. In the CM of the four cell lines, 25.9% -28.5% of the identified proteins were known to be secreted or predicted to be secreted, and 38.9% -39.4% were categorized as plasma membrane proteins, together accounting for 65.3% -67.7% of the total ( Figure 2B ). The remaining proteins were either intracellular (29.7% -31.6%) or unknown (2.6% -3.1%). The spectral counts of protein in the 1D GeLC-MS/MS analysis are indicative of protein abundance. Therefore, we performed subcellular localization analysis of the identified proteins weighted with their corresponding spectral counts as well, and found that 42.3% -49.0% of the spectral counts were attributed to secreted proteins ( Figure 2C ). The fractions of secreted proteins weighted by spectral counts were significantly higher than the unweighted fractions, suggesting that these proteins were more abundantly detected in the CM. Indeed, the average spectral counts of secreted proteins were in general more than 2 folds higher than those of other proteins in the four cell lines (P < 1 × 10 -5 ).
Identification of bone metastasis-associated proteins
Next, we compared the secretomes of these cell lines to search for the proteins associated with bone metastasis, with an emphasis on secreted proteins. As shown in Supplementary information, Figure S1 , 1 761 proteins were detected in the CM of weakly metastatic cells SCP4 and SCP6, and 1 708 proteins detected in that of bonetropic cells SCP2 and SCP46. Subcellular localization analysis identified 468 and 473 secreted proteins in each group. We compared the abundance of these proteins in the CM of two cell groups and found that 128 proteins were differentially secreted with spectral count fold changes > 2 and Student's t-test P values < 0.05, among which 69 proteins were up-regulated and 59 down-regulated in metastatic cells (Supplementary information,  Tables S1 and S2 ). Previously Kang et al. [29] have analyzed the transcriptomic changes of these same cell lines. Therefore, we analyzed whether the alterations of metastasis-associated secreted proteins can be explained by transcriptional regulation. First, we performed the Gene Set Enrichment Analysis [35] to assess the global gene expression pattern of the 69 up-regulated and 59 down-regulated proteins. As a whole group, the up-regulated proteins were significantly enriched at their mRNA levels in the metastatic cells, and conversely the down-regulated proteins were enriched in the weakly metastatic cells (P < 10 -3 , Figure  3A ). Then we analyzed the overlap of bone metastasisassociated proteins with the bone metastasis gene signature previously identified by the transcriptomic analysis [29] . The transcriptomic signature consisted of 106 unique genes, 28 of which encode secreted proteins. Ten (35.7%) of these secreted proteins were found in the list of regulated proteins by the proteomic analysis (Supplementary information, Table S1 ), an overlap significantly higher than random chances (P = 6 × 10 -10 ). Reciprocally, 33 (25.8%) of the metastasis-associated secreted proteins were regulated transcriptionally with RNA fold changes > 2. However, 78 altered proteins were not regulated obviously in the transcriptional level, and 2 proteins displayed opposite transcriptional alterations, together accounting for 62.5% of the identified proteins (Supple- Table S1 ). The other 15 proteins did not have corresponding microarray probes in the transcriptomic analysis. Therefore, both transcriptional and post-transcriptional regulations were responsible for the alterations of protein secretion during metastasis.
We then performed Gene Ontology (GO) analyses on biological processes and molecular functions of the 128 metastasis-associated proteins. The top enriched biological processes in these proteins were frequently related to cell adhesion and movement (Supplementary information, Figure S2 and Table S3 ). Molecular function analysis showed that the regulated proteins were Figure 3B and Supplementary information, Table S4 ), arguing that the extracellular signaling connecting tumor and stromal cells was vital to regulate breast cancer metastasis to bone. Interestingly, other significantly enriched molecular functions of the metastasis-associated proteins were largely involved in regulation of protease activities, especially protease inhibition ( Figure 3B ). Twelve proteinase regulators, including 4 members of the cystatin family (CST1, CST2, CST4, CST6), 3 members of the serpin family (SERPI-NA1, SERPINE2, SERPINI1), KAL1, COL7A1, TIMP3, MMP14 and PROS1, were significantly regulated in the secretomes of bone-tropic breast cancer cells (Table 1 ). All but one (MMP14) of these regulators were inhibitors of proteinases, such as cysteine proteinases, serpin peptidases and metalloproteinases, suggesting the roles of these proteinases in shaping the tumor microenvironment during the spreading of cancer cell to bone.
CST6 expression and secretion are negatively correlated with bone metastasis
In the list of bone metastasis-associated secreted proteins, the most well-represented proteinase inhibitor family was cystatins, the type 2 members of the cystatin superfamily [36] . Cystatins are endogenous inhibitors of lysosomal cysteine proteinases including cathepsins, papain and legumain. These proteinases and cystatins counteracted each other to tailor the proteolytic activities inside and outside the cells, which is critical for cell signaling, apoptosis, ECM modeling and tumorigenesis [36] . Our proteomics data indicated that these proteins might also play important roles in breast cancer bone metastasis. Four cystatins, namely CST1, CST2, CST4 and CST6, were aberrantly regulated in the CM of bonetropic cells. CST6 secretion in bone-metastatic cells was suppressed, while secretions of the other three cystatins were elevated. Therefore, we focused on these cystatins for further screening. We first validated the secretion levels of cystatins in the CM of cancer cells by western blot analysis. Consistent with the proteomic analysis, CST1, CST2, CST4 were abundantly present in the CM of bone-metastatic cells SCP2 and SCP46, while they were significantly less secreted by the weakly metastatic cells SCP4 and SCP6. In contrast, both forms of the CST6 protein, the 14 kD form and the glycosylated 17 kD form, were readily observed in the CM of SCP4 and SCP6, whereas neither form could be detected in the CM of SCP2 or SCP46 ( Figure 4A ).
Next we tested the cystatin mRNA expression in a wider array of breast cancer cell lines with different metastasis potentials. In the MDA231 SCP derivatives, the expression patterns of cystatins were generally consistent with their secretion levels. CST1 and CST4 were expressed more abundantly in SCP2, SCP46, and another two bone-tropic lines SCP20 and SCP25, than in SCP4, SCP6 and another mildly metastatic line SCP28. CST2 displayed a similar expression pattern, albeit without statistical significance. In contrast, CST6 was expressed only in the weakly or mildly metastatic cells, but not in the highly metastatic cells ( Figure 4B ). We further analyzed transcriptomic microarray data for a separate group of 18 in vivo selected MDA231 derivative cell lines, including the weakly metastatic lines 1834, 2293, 2295, 2297, 4142, 4180 and the bone-tropic lines 1833, 2268, 2269, 2271, 2274, 2287, PD1, PD2A, PD2B, PD2C, PD2D, PD2E. These cell lines were either obtained by in vivo selection of rare cell variants pre-existing in the MDA231 population [29] , and Kang et al., personal communication), or resulted from in vivo evolution of non-metastatic cells after a long-term dormancy [37] . In this cell group representing two model systems for breast cancer bone metastasis that are distinct from the SCP derivatives, the expression of CST6 by the bone-tropic cells was consistently weaker than that by the non-metastatic cells. However, the mRNA expression levels of other cystatins were not correlated with cancer cell bonetropism ( Figure 4C ). We also examined the expression of cystatins in the MCF10 cell line series including MC-F10AT, MCF10CA1h and MCF10CA1a. These isogenic human breast cancer cell lines display progressively increased metastatic malignancy when injected into immunodeficient mice. The CST6 expression level was much higher in the less malignant MCF10AT than in the other two lines ( Figure 4D ), but other cystatins did not show any difference in their expression (data not shown). In addition, the CST6 extracellular protein level declined gradually in the MCF10 series, but with a lesser extent of glycosylation than in the MDA231 derivatives ( Figure  4A ). Therefore, the CST6 expression was consistently correlated with metastasis in different cell models.
It has been reported that the CST6 gene was often silenced by DNA methylation in breast cancer cells [38, 39] . Thus we studied the methylation levels of a CpG island on the CST6 promoter in MDA231 derivative cells by methylation-specific PCR (MSP) and bisulfite sequencing. Both assays showed that the CST6 promoter was specifically methylated in the metastatic cells ( Figure  4E and Supplementary information, Figure S3 ). The first 3 CpG loci were heavily methylated in SCP2, SCP46 and SCP25 in which CST6 was not expressed, while methylation of these loci was rarely observed in the CST6-expressing SCP4, SCP6 and MDA231 parental cells (Supplementary information, Figure S3 ). We then analyzed the clinical significance of CST6 expression in human breast tumors with Kaplan-Meier Plotter, an online tool to evaluate the correlation of gene expression with breast cancer prognosis in over 2300 clinical samples [40] . With this tool, we found that lower expression of CST6 was linked to markedly higher risk of breast cancer recurrence (hazard ratio = 0.71, P = 3.5 × 10 -5 ), establishing CST6 as a prognosis marker for breast cancer ( Figure 4F ). We further compared the CST6 expression in breast cancer primary tumors and bone metastases from a clinical microarray dataset [41] and found that CST6 was down-regulated in the bone metastasis tissues (Supplementary information, Figure  S4 ). Therefore, we focused on CST6 for functional validation in the further studies.
CST6 inhibits in vitro migration and invasion of breast cancer cells
CST6 has been previously noticed to be down-regulated in malignant breast tumor cells [42, 43] . However, its functional role in metastasis, especially in bone metastasis, has yet to be fully characterized. We first stably overexpressed CST6 in the highly metastatic SCP2 cells with a retroviral plasmid. Real-time PCR and western blot analyses confirmed that CST6 was overexpressed, which led to the elevated secretion of the protein ( Figure  5A ). We also confirmed that the ectopic CST6 protein was biologically functional in that it inhibited the enzymatic activities of cathepsin B (CTSB) and L (CTSL), two of its target proteinases ( Figure 5B ). CST6 overexpression suppressed cancer cell growth and soft-agar colony formation ( Figure 5C and 5D), suggesting a role of CST6 in breast cancer tumorigenicity. We then tested the effect of CST6 overexpression on cell migration via the wound-healing assay and observed nearly 50% impairment of cell motility by CST6 ( Figure 5E ). By twochamber transwell assays, we also found that CST6 diminished SCP2 migration by 8-fold ( Figure 5F ) and invasiveness by 3-fold ( Figure 5G ). The suppressive role of CST6 in cancer cell invasion was also observed when
npg we overexpressed CST6 in another breast cancer cell line MCF10CA1h. CST6 overexpression in MCF10CA1h resulted in elevated CST6 secretion and significantly reduced cell invasion ( Figure 5H ). To determine whether CST6 inhibition was sufficient to promote cancer cell malignancy, we used two independent short hairpin RNA (shRNA) constructs to knock down CST6 in SCP4 cells. Both constructs efficiently silenced CST6 in SCP4 and abrogated the secreted protein in CM ( Figure 6A ). Concordant to the observations after CST6 overexpression, CST6 knockdown in SCP4 promoted cancer cell proliferation, soft-agar colony formation, wound-healing motility, transwell migration and invasion ( Figure 6B-6G) . We also knocked down CST6 in MC-F10AT that expressed CST6 abundantly and found a similar phenotype ( Figure 6H ), suggesting that breast cancer cells indeed acquire malignant traits by silencing CST6.
Although the overexpression and knockdown experiments proved that CST6 functioned to repress cancer cell malignant progression, it was still unclear whether CST6 exerted its roles inside the cells or extracellularly. Thus we tested the CST6 protein function in the cancer cell culture medium. The CM of SCP2 overexpression cells contained a higher concentration of CST6 than that of the control cells ( Figure 5A ). Thus we tested the transwell migration capability of untransfected SCP2 in the CM of SCP2 control and overexpression cells. The CM containing abundant CST6 protein significantly attenuated the migration of SCP2 cells ( Figure 7A) . Conversely, when we knocked known CST6 in SCP4 to abolish the CST6 protein in the CM, the SCP4 CM could result in substantially elevated migration of SCP2 cells ( Figure 7A ). We performed these experiments again for SCP4 cells cultured in the same collection of CM. Consistently, cancer cells seeded in CM without the CST6 protein displayed much higher migratory capabilities ( Figure 7B ). In addition, when SCP2 or SCP4 cells were cultured in the CM of SCP4, they migrated slower than the same cells cultured in the CM of SCP2 that contained less soluble CST6 ( Figures 4A, 7A and 7B) . Further, we used a neutralizing anti-CST6 antibody to block the CST6 protein in the CM of CST6-overexperssion cells, and found that the migration-inhibitory effect of the CM could be reversed completely by the antibody in a dose-dependent manner ( Figure 7C ). The neutralizing antibody was also able to abolish the migration-inhibitory effect of the CM from SCP4 cells ( Figure 7D) . However, when the soluble CST6 was ablated from the SCP4 CM by shRNA knockdown, the neutralizing antibody had no effects on cell migration ( Figure 7D ). Taken together, these data showed that secreted CST6 suppressed cancer cell migration.
In addition to cancer cells, stromal cells could also contribute to the secreted factors in the tumor microenvironment. We then analyzed whether other cell components of breast tumor tissues secret CST6 by western blot and immunohistochemistry analyses. It was shown that only normal mammary epithelial cells and tumor cells expressed CST6, while cell lines of the M2 macrophage, endothelium, fibroblast or stromal cells surrounding breast tumors did not secret visible levels of CST6 (Supplementary information, Figure S6 ), which is consistent to previous findings regarding the tissue specificity of CST6 expression [44, 45] . 
CST6 suppresses breast cancer bone metastasis
We further tested the in vivo function of CST6 in breast cancer using a xenograft mouse model. We first injected the SCP2 cells with or without CST6 overexpression into the mammary fat pads of nude mice, and found that primary tumor growth was greatly impaired by CST6 ( Figure 8A ). We then examined the effect of CST6 on metastatic tumor growth at distant organs. The SCP2 cells were labeled with a plasmid construct expressing firefly luciferase and injected into the left ventricle of nude mice for bone metastasis analyses. The bone metastasis burden of mice was quantitated weekly by noninvasive bioluminescent imaging (BLI). CST6 expression in the cancer cells markedly reduced metastasis signals in the spine and limbs ( Figure 8B , 8C and Supplementary information, Figure S7 ). By the 10th week after cancer cell injection, the metastasis burden caused by CST6-expresssing cells was nearly 10 times weaker in the spine and 20 times weaker in hindlimbs than that by control cells. The control SCP2 cells resulted in severe osteolytic bone lesions and massive bone destruction in the femurs at that time. In contrast, the cells expressing CST6 led to much milder bone damages and tumor lesions ( Figure  8B and 8C) . In addition, when we extracted the bone marrow from the femur and tibia at the 10th week and seeded the marrow in culture medium supplemented with puromycin that would eliminate all host cells, much fewer cancer cell colonies grew from the marrow of mice injected with CST6-expressing cancer cells ( Figure 8B ). Moreover, CST6 overexpression significantly prolonged mouse survival after cancer cell implantation. Eight of 9 (89.9%) mice bearing the control SCP2 cells died from severe metastasis burden 15 weeks post injection, while only 1 of 8 (12.5%) mice succumbed to the CST6-expressing cells at the same duration ( Figure 8D ).
We then tested the metastasis effect of CST6 knockdown in the SCP4 cells. Both CST6 shRNA constructs in the cancer cells resulted in more aggressive metastasis in the spine and limbs of nude mice ( Figure 8E and Supplementary information, Figure S7 ). At the 10th week after injection, the control SCP4 cells only led to minor bone damages in the limbs. The tumor lesions remained mostly within the bones. In contrast, the mice injected with CST6-knockdown cells suffered from widely-spread metastatic tumors and immense bone loss in the femurs and tibia. CST6 knockdown also accelerated animal deaths ( Figure 8F ).
To further analyze the effect of CST6 on osteolysis during bone metastasis, we performed TRAP staining on the metastasis tumors to assess the mature osteoclasts along the interface of tumor cells and bone matrix. We found that CST6-expressing cancer cells were surrounded by markedly less osteoclasts as compared to the control cells, while CST6 knockdown led to increased numbers of osteoclasts ( Figure 8G) . Collectively, the animal studies demonstrated that CST6 significantly suppressed os- 
Discussion
In this study we systemically analyzed the tumor secreted proteins that were associated with breast cancer bone metastasis. To our knowledge, this is the first fully published secretome study for bone metastasis of breast cancer. The skeleton is the major target site of metastasis for many types of cancer including breast cancer [2] . Elucidating the secretomic anomaly of tumor cells during skeleton metastasis may help decipher the molecular events that enhance the compatibility of metastasizing cancer cells and bone stroma. More importantly, given the nature of secreted proteins to be readily detected and readily targetable by therapeutics, the identification of bone metastasis-specific secreted proteins will provide us a good source of candidate molecules for prognosis prediction and anti-cancer intervention.
Previous transcriptomic studies of breast cancer metastasis organotropism have led to the identification of a number of molecules that are correlated with metastasis to various organs such as the lungs, bone and brain [29, 46, 47] . Comparison of the bone metastasis protein signature with the transcriptomic signature identified by gene expression profiling revealed 10 proteins that were regulated concordantly in the transcriptional level and the secretion level. Many of them, such as ADAMTS1, CTGF, IL11 and MMP1, are well-proven functional mediators of metastasis [29, 48] . However, transcriptional regulation could only explain approximately one quarter of the secretomic difference. The transcriptional alterations of 74.2% of bone metastasis-specific secreted proteins were either unknown, not obvious, or even opposite to the proteomic analysis results, indicating an important role of post-transcriptional regulation for metastasis-related secretion. Some of these molecules, such as JAG1 and IGFBP3 [31, 49] , have been already demonstrated to impact the metastasis of breast cancer cells. Therefore, the discovery of metastasis-specific regulation at the protein level will not only bring in novel candidates of metastasis functional molecules, but also improve our understanding of the metastasis process from a different angle.
In addition to the aforementioned proteins that are proven functional molecules in bone metastasis, some proteins in the regulated list, such as BMP1, BMP4, TIMP3, ITGA3 and ICAM2, are promising candidates for further studies. BMP1 and BMP4 are potent regulators of bone formation and have been implicated in skeleton metastasis [50] . TIMP3 regulates bone formation and excessive TIMP3 in bone may induce osteoblast differentiation, leading to depletion of osteoblast progenitors in the bone marrow [51] . ITGA3 is the receptor for collagen and thus can mediate the interaction of cancer cells to ECM. ICAM2 regulates the cell cytoskeleton reorganization and suppresses neuroblastoma metastasis [52] . Therefore, these proteins are likely to promote or suppress bone colonization of breast cancer cells. Validation of their roles in metastasis and elucidation of the functional mechanisms will greatly help to understand the biology underlying bone complication of breast cancer.
Cysteine proteinases, serpin peptidases and metalloproteinases are known to play critical roles in tumor initiation, progression and metastasis [9, [53] [54] [55] . The search for chemical compounds to inhibit these proteinases is a topic of constant interest for anti-cancer therapeutics [56, 57] . Notably, the bone metastasis-specific proteins identified in our proteomic study are enriched with the regulators of these proteinases. This data indicated that not only the proteinases but also their endogenous regulators were subject to tight regulation during metastasis, suggesting a new direction for drug designing to target proteinases in therapeutics.
CST6 is the natural inhibitor of lysosomal proteases CTSB, CTSL, cathepsin V (CTSV) and legumain (LGMN). Its physiological expression is restricted to mammary epithelium, the stratum granulosum of skin epidermis, sweat glands, hair follicle and nail [44, 45] . The balance of CST6 and its target proteinases is essential for the homeostasis of these tissues [44, 58] . CST6 knockout in mice causes neonatal lethality due to excessive transepidermal water loss [59] . In this work, we selected CST6 for functional validation in breast cancer bone metastasis, due to the fact that the cystatin family proteins were collectively regulated in bone metastasis and, in particular, CST6 was consistently correlated with breast cancer metastasis in a wide range of cell lines and clinical samples. Disregulation of cystatins in cancer cells has been widely reported [36] . Among them, CST6 is generally regarded as a tumor suppressor as it is often silenced in tumor cells, especially in metastatic cells [42, [60] [61] [62] [63] . However, the observations in CST6 functional analyses have been conflicting. While some studies reported the suppressive roles of CST6 in tumor cell proliferation, migration and invasion of several cancer types [42, 64, 65] , it was also found to promote pancreatic cancer growth [66] . In breast cancer, CST6 was originally identified as a gene down-regulated in a metastatic cell line as compared to its matched primary tumor cell line [67] [68] [69] [70] [71] . Since then, data have been accumulated to show its silencing, mostly by epigenetic regulation, in breast cancer [72] , whereas few studies reported the functional characterization of CST6. The functions of CST6 in breast cancer have been tested mainly in the MDA-MB-435 cell line, demonstrating that CST6 overexpression delayed the metastasis growth in lungs and liver but had no effect on the metastasis incidence in these organs [73] . However, the lineage fidelity of MDA-MB-435 to breast epithelium is currently in debate [74] . In addition, the function analysis was performed exclusively by forced expression of CST6, and it has been unclear whether cancer cells can acquire malignant traits by CST6 loss. Therefore, solid evidence is yet needed to support the function of CST6 in breast cancer metastasis, especially to bone. Furthermore, it is unknown how CST6 plays its roles in metastasis.
We performed rigorous functional analyses and found that CST6 suppressed cancer cell proliferation, colonyformation, migration and invasion. The phenotypes were observed with both approaches of overexpression and knockdown. Ectopic expression of CST6 weakened the aggressiveness of cancer cells, while two independent knockdown constructs of CST6 resulted in increased malignancy. More importantly, the CST6 displayed an obviously suppressive role to breast cancer bone metastasis in the animal studies. While control SCP2 cells formed metastasis rapidly in spine and limbs of nude mice and caused massive osteolysis, the same cells with CST6 overexpression showed significantly weaker virulence in the animals. In addition, the mice were rescued from metastasis-caused deaths by CST6 overexpression. Moreover, CST6 inhibition by shRNA in a less virulent cell line SCP4 caused the opposite changes, documenting the evidence that loss of CST6, a phenomenon often observed in aggressive breast carcinoma, confers the cells more malignant traits including bone-tropism. Therefore, our study firmly established CST6 as a suppressor of breast cancer bone metastasis.
In addition, we showed that CST6 exerted its function in the extracellular space. The CM containing high or low levels of soluble CST6 protein caused the cancer cells to migrate differently, and blocking the secreted CST6 by a neutralizing antibody abolished such difference. We could not rule out the possibility that intracellular CST6 plays a role in metastasis as well. Nevertheless, secreted CST6 was shown to suppress breast cancer bone metastasis. This is important for CST6 to be considered as a prognosis marker or a druggable molecule, as it is much easier to detect CST6 in the serum or body fluid than in tumor cells, as well as to deliver the recombinant CST6 or the inhibitors of its downstream proteinases to the extracellular space.
Intriguingly, 3 other family members of cystatins, CST1, CST2 and CST4, displayed a disregulation pattern totally opposite to that of CST6 in metastasis. Although CST1/2/4 were also lysosomal protease inhibitors as CST6, they may have different target specificities. Previous studies reported that CST6 inhibits CTSB, CTSL, CTSV and LGMN, while the other cystatins primarily target on papain, ficain, with CST1 inhibiting CTSB as well [75] . Indeed, our analysis demonstrated that SCP2 and SCP4 cells expressed and secreted these proteinases at various levels. CST6 inhibited CTSB and LGMN efficiently, but CST1 only suppressed the enzymatic activity of CTSB and the other two cystatins had no effects on either proteinases (Supplementary information, Figure S5) . Therefore, the difference in target preference might provide an explanation of the marked discrepancy in the secretion of cystatin proteins, which, however, is to be further studied.
In conclusion, this study identified the secreted proteins that were regulated during breast cancer bone metastasis in an isogenic cell line model. Caution needs to be taken to interpret these results as cell line models may not well represent the clinical metastatic disease. Nevertheless, these candidate proteins hold great promise to further investigate the molecular underpinning of breast cancer bone tropism. In addition, this study revealed CST6 as a metastasis suppressor that is silenced in breast tumor cells metastatic to bone. Therefore, it potentially can serve as a prognosis biomarker, and can be applied in cancer therapeutics with approaches such as gene therapy or recombinant protein delivery. Future work is needed to define its downstream effectors so that alternative therapeutic methods can be used to block the metastasis pathways that are naturally inhibited by CST6.
Materials and Methods
Cell culture
MDA231 parental and derivative cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, HyClone) supplemented with 10% fetal bovine serum (FBS, HyClone), 100 units/ ml penicillin and 100 µg/ml streptomycin (Invitrogen) in 5% CO 2 at 37 °C. MCF10 cell line series were maintained in DMEM/F12 medium supplemented with 5% horse serum, 10 μg/ml insulin (Roche), 20 ng/ml epidermal growth factor (Invitrogen), 100 ng/ ml cholera toxin (Merck), 0.5 µg/ml hydrocortisone (Enzo), penicillin and streptomycin. For bioluminescent imaging, cell lines were retrovirally infected with a fusion protein construct encoding the green fluorescent protein and the firefly luciferase.
Plasmids and antibodies
Human CST6 was cloned into the pMSCVpuro plasmid (Clontech) for overexpression. CST1, CST2, and CST4 overexpression plasmids were kind gifts from Dr Yibin Kang at Princeton University were 5′-GCCGTATCTGTCACAATAA-3′ (KD1) and 5′-GTGGT-TCCCTGGCAGAACT-3′ (KD2). The shRNA sequences were cloned into the pSuper-Retro-Puro retrovirus vector (OligoEngine). The goat anti-human CST6 (R&D Systems) was used in this study for western blot, immunohistochemistry and neutralizing analyses. The rabbit anti-human CST1 (Proteintech), rabbit antihuman CST2 (Proteintech), rabbit anti-human CST4 (Abgent), mouse anti-human CTSL (R&D), goat anti-human CTSB (R&D) and goat anti-human LGMN (R&D) were used for western blot.
CM collection
Cells were grown to ~80% confluence in 10 cm culture dishes. After washing with serum-free medium at 37 °C for 15 min twice and 60 min twice, the cells were incubated in serum-free medium at 37 °C for 24 h. The cell death rate was controlled at below 3% (measured by trypan blue staining). The CM were collected, centrifuged at 1 000 rpm for 10 min, filtrated by 0.22 µm filters, and then added with protease inhibitors (Roche). The collected CM were stored at −80 °C until used.
One-dimensional gel electrophoresis and in-gel digestion
The CM were concentrated with the Ultra-15 centrifugal filter devices with the 3-kD cutoff (Millipore), and the protein concentration was determined by Bradford assay. Concentrated CM containing 35 µg proteins of each sample were subjected to SDS-PAGE and stained with Coomassie blue. After extensive decolorization, each lane was excised into 12 sections. Each section was cut into ~1 mm cubes and destained by incubation using 50% acetonitrile in 50 mM ammonium bicarbonate. After destained, the gel pieces were reduced by incubation in a solution of 50 mM Tris (2-carboxyethyl) phosphine in 25 mM ammonium bicarbonate at 60 °C for 10 min. For alkylation of proteins, the gel was incubated in 100 mM iodoacetamide (IAA) at room temperature for 60 min, followed by washing with 50% acetonitrile in 50 mM ammonium bicarbonate twice. The gel pieces were then dehydrated in 100% acetonitrile for 15 min, dried completely by SpeedVac, swollen in 50 µl of 25 mM ammonium bicarbonate containing 0.01 µg/ µl trypsin (Promega) and incubated overnight at 37 °C. Peptides were extracted with 50% acetonitrile containing 5% formic acid four times, dried by vacuum centrifugation at 60 °C, and stored at −20 °C for further analysis.
Nano LC-MS/MS
All nano LC-MS/MS experiments were performed on the MDLC system (Michrom Bioresources Inc.) coupled with a Thermo Finnigan 2-D linear ion trap mass spectrometer (LTQXL, Thermo Inc.). The trypsin-digested dry sample was dissolved in 30 µl 5% acetonitrile with 0.1% formic acid, and 20 µl of this peptide solution was loaded onto a Peptide Captrap column (Michrom Bioresources Inc.) with the autosampler of the MDLC system. To desalt and concentrate the sample, the trap column was washed with 5% acetonitrile containing 0.1% formic acid at a flow rate of 10 µl/min for 10 min. Then the trapped peptides were released and separated on a C18 capillary column (0.1 mm i.d. × 150 mm, 3 µm, 200 Å, Michrom Bioresources Inc.). The flow rate was maintained at 500 nL/min. Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile. The eluted gradient was started at 5% B, reached 35% B in 120 min, then 80% B in the next 2 min. The LC setup was coupled online to a LTQ using a nano-ESI source (ADVANCE, Michrom Bioresources Inc.) in the data-dependent acquisition mode (m/z 400-1800). The temperature of heated capillary was set at 200 °C and spray voltage was 1.2 kV. The mass spectrometer was set as one full MS scan followed by ten MS/MS scans on the ten most intense ions from the MS spectrum with the following dynamic exclusion settings: repeat count = 2, repeat duration = 15 s, exclusion duration = 30 s.
Protein identification
All data files were created by searching MS/MS spectra against the Human International Protein Index protein sequence database (IPI.Human.v3.67.fasta, 84118 entries), using the TurboSEQUEST program in the BioWorks 3.3 software suite, with a precursor-ion mass tolerance of 2.0 amu and fragment-ions mass tolerance of 0.8 amu. Trypsin was set as the protease with two missed cleavage sites allowed. Carbamidomethylation (+57.02150 Da) was searched as a fixed modification on cysteine, representing alkylation with IAA, while oxidized methionine (+15.99492 Da) was searched as variable modifications. The searched peptides and proteins were validated by PeptideProphet1 and ProteinProphet2 in the Trans-Proteomic Pipeline (TPP, v. 4.2) using default parameters. Proteins with ProteinProphet P-value greater than 0.9 and no less than three kinds of unique peptides were considered as true identifications. Randomized IPI.HUMAN.v3.67. fasta was used as a decoy database to estimate the false discovery rate (FDR) of protein identification. The FDR was calculated as the ratio of the number of matches on the randomized database to the sum of randomized matches and observed matches. FDR for ProteinProphet 0.9 in our analysis was < 1%. Proteins containing the same peptides were grouped, and only one protein with the highest probability in each group was remained.
Secretome data analysis
To compare the secretomes from cell lines with different metastasis properties, the spectral counts of each cell line were normalized and the protein fold changes in two cell line groups were calculated as previously described. The cutoffs of fold changes ~ 2 and Student's t-test P ~ 0.05 were used to select the bone metastasis associated proteins.
The subcellular localizations of identified proteins were classified as secreted (predicted secreted), plasma membrane and intracellular. A protein was classified as secreted if it was designated as "extracellular" by the GO term, or as "secreted" in the UniProt database (http://www.uniprot.org/), or predicted as so by SignalP 3.0 (probability ~ 0.90) or SecretomeP 2.0 (NN-score ~ 0.50). A protein was classified as plasma membrane with its GO designation of "plasma membrane", or UniProt description of "cell membrane", or predicted by TMHMM 2.0 (http://www.cbs.dtu. dk/services/TMHMM/). Intracellular proteins were identified via their GO and UniProt designation. Unknown proteins were those that could not be classified by above sources.
Gene Ontology analysis of the biological processes and molecular functions were performed with the tool GOEAST (http:// omicslab.genetics.ac.cn/GOEAST/index.php).
Immunoblot analysis of secreted proteins
To precipitate secreted proteins, 0.5 ml of 40% trichloroacetic acid was added to 0.5 ml CM. After incubation on ice for 1 h, the samples were spun at 14 000× g for 30 min and the supernatants were discarded. Pellets were washed twice by spinning at 14 000× g for 5 min in cold acetone and re-suspended in SDS loading buffer. The proteins were separated by 15% SDS-PAGE and transferred onto a polyvinylidene filter using Mini Trans-Blot (Bio-Rad Laboratories). The filter was stained with Ponceau S and blocked by 5% nonfat milk in Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature. The filter was then incubated with a primary antibody overnight and washed, followed by blotting with a secondary antibody conjugated with HRP for 1 h. The signals were visualized with chemiluminescent HRP substrate (Millipore).
MSP and bisulfite sequencing
One μg of extracted DNA was modified with sodium bisulfite using the EZ DNA Methylation Gold Kit (ZYMO) according to the manufacturer's instructions. The CST6 primers for the methylation-specific reaction were 5′-TGGTCGGTATTAAGT-ATTTTTTGAC-3′ (sense) and 5′-AACCCAACTATTACCTC-CTACTACG-3′ (antisense), and those for the unmethylation-specific reaction were 5′-GTTGGTATTAAGTATTTTTTGATGA-3′ (sense) and 5′-AACCCAACTATTACCTCCTACTACAC-3′ (antisense). For bisulfite sequencing, the fragment covering the CpG island of CST6 promoter was amplified from bisulfite-modified genomic DNA with primers 5′-GGAAATGGTGGTAATAG-TAAGAGTTTA-3′ (sense) and 5′-AAATTCAAAAAACCCA-AAAAACC-3′ (antisense). The PCR products were cloned into pcDNA3 vector, and 8-10 clones of each sample were sequenced.
Colony formation assay
Cells were suspended in DMEM containing 0.3% agarose gel (Invitrogen) at a concentration of 2 × 10 3 cells/ml. The suspension was seeded in a plate coated with 0.6% solidified agarose. The cells were incubated for 4 weeks before the colonies were counted and photographed with a Leica microscope.
Wound-healing assay
Cells were grown into confluence in 6-well plates. The monolayer was artificially injured by scratching across the plate with a 200-µl pipette tip. The wells were washed 3 times to remove detached cells or cell debris. After 12 h, images of the scratched areas were photographed. Scratch wound areas were measured and the migration distances were calculated as initial wound sizefinal wound size.
In vitro migration and invasion assays
Migration assays were conducted using transwells with polycarbonate membrane filters of 8-µm pore sizes (Costar, Cambridge, MA) in 24-well culture plates. For invasion assay, the upper chamber was coated with 40 μl Matrigel (Becton Dickinson, Bedford, MA). After being starved in FBS-free medium overnight, the cells were seeded in the upper chamber at a density of 10 5 cells per well. FBS was used in the lower chamber as the attractant. Cells that migrated or invaded into the lower surface were counted 24-48 h later. Random fields were photographed after crystal violet staining. Experiments were performed at least in triplicates.
For CM migration analysis, the serum-free CM from various cell lines were used in the upper and lower chamber of the transwell, and FBS was added into the lower chamber as the attractant.
Proteinase enzymatic activity assay
Cathepsin B (BioVision, K140-100) and cathepsin L (BioVision, K142-100) assays were performed with the activity assay kits according the manufacturer's instructions in 96-well plates. The assays were measured with a fluorometer (TECAN Safire 2, USA) equipped with a 400-nm excitation filter and a 505-nm emission filter. The CTSB inhibitor (CA-074, Merck) and the CTSL inhibitor (Z-FY[t-Bu]-DMK, Merck) were used as controls. The substrate Z-Ala-Ala-Asn-AMC (I1865, Bachem) was used for legumain activity assay with a 353-nm excitation filter and a 442-nm emission filter.
Animal studies
All animal experiments were performed in compliance with the guidelines for the care and use of laboratory animals and were approved by the institutional biomedical research ethics committee of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Female Balb/c nude mice (4-6 weeks old) were used in all animal studies.
To study primary tumor growth, cells were harvested by trypsinization, washed twice in PBS and counted. Cells were then resuspended (1 × 10 7 cells/ml) in 1:1 mixture of PBS and Matrigel. Mice were anaesthetized by 1% Pelltobarbitalum Natricum. A small incision was made to reveal the 4th mammary fat pad and 10 5 cells (10 μl) were injected directly into the fat pad. The incision was closed and tumor growth was monitored weekly by measuring the tumor length (L) and width (W). Tumor volumes were calculated as πLW 2 /6. For bone metastasis studies, 10 5 tumor cells in PBS (100 μl) were injected into the left cardiac ventricle of anesthetized mice. At each week, the anesthetized mice were retro-orbitally injected with 75 mg/kg D-Luciferin (Caliper Life Sciences), and BLI data was acquired with a Berthold NC100 Imaging System. Bone damages were monitored by X-ray radiography. Mice were anesthetized, arranged in prone position on single-wrapped films (X-OMAT Kodak) and exposed at 24 kV for 180 s with a Faxitron instrument (Faxitron Bioptics). Films were developed using a Konica SRX-101A processor and inspected for visible bone lesions. Osteolytic areas were identified on radiographs as demarcated radiolucent lesions in the bone and quantified using the Image J software (NIH).
Histological analysis and TRAP staining
Forelimb and hindlimb long bones of nude mice were excised, fixed in 10% neutral-buffered formalin, decalcified (10% EDTA, 2 weeks), dehydrated through a graded alcohol series, then embedded in paraffin and stained with hematoxylin and eosin.
TRAP staining was performed with the tartrate-resistant acid phosphatase kit (Sigma 387A). Osteoclast numbers were assessed as multinucleated TRAP+ cells along the tumor-bone interface and reported as number/mm of interface. 
Statistical analysis
